Posts Tagged ‘Wegovy’

An End to Blathering About Obesity? Nope!

September 7, 2023 — The Wegovy brand of semaglutide has finally come to the UK this week – albeit in limited quantities. So in the Guardian, Zoe Williams wonders if this will mean the end to blathering about obesity: “Despite this being a breakthrough, it is going to pose an immense challenge to those, in medicine and beyond, who […]

Places with Wealth-Based Access to Diabetes and Obesity Care

August 27, 2023 — Writing for the New York Times, Joseph Goldstein tells us that prescriptions for GLP-1 agonists are going to the wealthiest, whitest, and healthiest neighborhoods in New York City. Neighborhoods where the medical need is greatest? Not so much. Though we might hope that advanced medicines for obesity and diabetes would go to places with the […]

Preventing Heart Attacks, Strokes, and Deaths by Treating Obesity

August 21, 2023 — How much might the application of new insights from the SELECT study of treating obesity do for preventing heart attacks, strokes, and deaths. A first pass at answering this question appeared in Cardiovascular Drugs and Therapy last week. Nathan Wong, Hridhay Karthikeyan, and Wenjun Fan estimated the potential for semaglutide treatment to lower cardiovascular disease […]

High U.S. Drug Prices, High Obesity Rates, Twisted Economics

August 19, 2023 — The intersection of high U.S. drug prices with its high obesity rates is creating some unusual economics. Kaiser Family Foundation (KFF) and the Peterson Center on Healthcare released an analysis this week that brings this into sharp focus. The analysis tells us that published prices for GLP-1 medicines used for obesity and diabetes are the […]

Obesity Medicines Price Shocks Hitting Employers

August 3, 2023 — Message to University of Texas Employees: Continuing to pay for obesity medicines is unsustainable. Message from Novo Nordisk: No comment. Price shocks for advanced obesity medicines are hitting employers. Things are starting to get messy in the marketplace and you can be pretty sure that they will only get messier as makers of obesity medicines […]

Will Broader Access Beget Lower Prices for Obesity Meds?

July 10, 2023 — In thoughtful reporting for Fortune, Rachel Shin explores the possibility for broader access to advanced obesity meds leading to lower prices. But it’s a bit of a chicken-and-egg puzzle because it might be more likely that lower prices will lead to broader access. Novopoly Shin calls it a Novopoly. Novo Nordisk invested billions of dollars […]

Get Ready to Argue About the SELECT Outcomes Study

July 8, 2023 — It’s coming. Sometime before September we will be hearing about the results of the SELECT outcomes study of semaglutide in people with obesity and we may as well start getting ready to argue about it now. Because value is in the eye of the beholder. And this study is all about the long-term health value […]

Why Ozempic Gets More Traction Than Wegovy

April 26, 2023 — Insights surface when we take the time to listen to people living with obesity. Yesterday, Ro and the Obesity Action Coalition released results from a study of the thoughts and feelings people are having about obesity, weight loss, and the new GLP-1 medicines. There’s a lot to think about in these results – about motivations […]

The Merger of Obesity and Diabetes

April 3, 2023 — This is a merger that has taken decades – the merger of obesity and diabetes. Ethan Sims first coined the term diabesity in 1973. Even five decades ago, the coincidence of diabetes and obesity was unmistakable, but the standards of care for obesity and diabetes did not reflect the recognition of obesity as anything other […]

Activating a UK Weight Loss Sensation Machine

February 15, 2023 — We can hear the rumble. The UK media sensation machine is gearing up for an onslaught of weight loss headlines that will misdirect millions of people about an important medical advance. If you have any doubt, sample the headlines from mainstream UK news sources. The Independent captures the spirit of British press on this subject […]